Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

25.0%

2 terminated/withdrawn out of 8 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

25%

2 trials in Phase 3/4

Results Transparency

75%

3 of 4 completed trials have results

Key Signals

2 recruiting3 with results

Enrollment Performance

Analytics

N/A
5(71.4%)
Phase 4
2(28.6%)
7Total
N/A(5)
Phase 4(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials
NCT07432659Not ApplicableRecruiting

Add-On ZIDA Sock Therapy for Overactive Bladder

Role: collaborator

NCT04000763Not ApplicableCompleted

Superficial Peroneal Nerve Neuromodulation for Non-Obstructive Urinary Retention

Role: collaborator

NCT04754737Not ApplicableRecruiting

Antibiotic Usage Prior to OnabotulinumtoxinA Injection

Role: collaborator

NCT03508921Phase 4Terminated

Comparison of Methods for Prevention of Urinary Tract Infection Following Botox Injection

Role: collaborator

NCT04063852Completed

PTNS on Urinary and Global Quality of Life in MS Patients

Role: collaborator

NCT03904407Not ApplicableCompleted

Optimizing Overactive Bladder Treatment

Role: collaborator

NCT02315560Not ApplicableCompleted

Foot Neuromodulation for Nocturnal Enuresis

Role: collaborator

NCT02176642Phase 4Terminated

Comparison of Combination Therapy vs Single Agent Therapy for Treatment of Urge Incontinence.

Role: collaborator

All 8 trials loaded